Double discovery thanks to iPS cells to research treatment into Down Syndrome

Publié le : 22 July 2014

 The Nature Communications journal has published an article in which scientists at the UC Davis School of Medicine and Schriners Hospitals for Children (North California) have just identified the role of astroglial cells (that support neurones) in the development of Down Syndrome and potential treatment of anomalies triggered by this condition. 

 
In order to arrive at this discovery, the scientists modelled the disease using stem cells harvested from Down Syndrome patients themselves. In other words, the scientists had recourse to induced pluripotent stem cells or iPS cells.  

Wenbin Deng, Accredited Professor of Biochemistry and Molecular Medicine, and the main author of the study explained: “We have developed a human cell model in order to investigate the development of the brain in Down Syndrome patients. This has allowed us to carry out detailed physiological studies and to establish potential new treatments“. Finally, he added that, “this model is far more realistic than traditional animal models because it is derived from the patients’ own cells“. 

 

The second discovery focuses on the potential influence of an antibiotic (minocycline) on these astroglial cells to correct abnormal interactions between these cells and the developing neurones. Once again, the use of iPS cells for molecular screening has proved critical.  

Share this article

BIOETHICS PRESS SYNTHESIS